Coincidentally, gemcitabine, the first‐line chemotherapy for PDAC, has been reported to deplete tumor‐infiltrating MDSCs at low doses.[18, 27] However, combining gemcitabine with AB680 did not result in a more significant decrease in tumor volumes compared to either treatment alone, as it weakened the efficacy of AB680 by reducing CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.